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Abstract
Background: Helminth infections and their components have been shown to have a protective effect on
autoimmune diseases. The isolated purified protein from Schisotosoma japonicum and its potential therapeutic
effect on trinitrobenzene sulfonic acid (TNBS)-induced colitis could provide an alternative way to treat inflammatory
bowel disease (IBDs).
Methods: Colitis was induced in Balb/c mice by rectal administration of 2.5 % TNBS, followed by intraperitoneal injection
of rSjcystatin 50 μg at 6 h and 24 h afterwards. The inflammation was monitored by recording weight change, stool
character and bleeding, colon length, macroscopic score (MAO), microscopic score (MIO), myeloperoxidase activity (MPO)
and disease activity index (DAI). The potential underlying mechanism was investigated by examining cytokine profiles
including Th1 (IFNγ), Th2 (IL-4), Th17 (IL-17A) and Treg subsets from lymphocytes of spleen, mesenteric lymph nodes
(MLN) and intestinal lamina propria mononuclear cells (LPMCs) by flow cytometry. The mRNA relative expressions of the
cytokines in splenocytes and MLN were analysed by quantitative real time reverse-transcriptase polymerase chain reaction
(qRT-PCR). Simultaneously, the concentrations of the cytokines in the colon homogenate supernatants were tested by
enzyme-linked immunosorbent assay (ELISA) and key transcription factors were detected by Western blotting.
Results: Administration of rSjcystatin significantly reduced inflammatory parameters and ameliorated the severity of the
TNBS-induced colitis through decreasing IFNγ in three organs and lifting the level of IL-4, IL-13, IL-10, and TGF-β in the
colon tissues, with uptrending Tregs in the MLN and LPMC.
Conclusion: The findings provide evidence that rSjcystatin has a therapeutic potential for diminishing colitis inflammation
in Balb/c mice. The immunological mechanism may involve the down-regulation of Th1 response and up-regulation of
Th2 and Tregs in the MLN and colon.
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Background
Inflammatory bowel disease is characterized by chronic
and recurrent inflammatory conditions of the intestinal
mucosa, containing two forms, ulcerative colitis and
Crohn’s Disease. The pathogenesis of IBD, however, re-
mains unclarified. Recent understanding of the IBD eti-
ology includes combined factors of an individual’s
genetics, environmental factors, immune dysregulation,
barrier dysfunction and disorder in microbial flora in in-
testine [1–3], that trigger aggressive cellular immune re-
sponses by innate cells, such as dendritic cells and
macrophages, leading to production of nitric oxide (NO)
and tumor necrosis factor alpha (TNF-α). Intense intes-
tinal inflammation was then initiated by the adaptive im-
mune system that followed [4–6], resulting in stronger
production of inflammatory factors such as IFNγ and
IL-17A by T helper cells [1].
The incidence of IBDs has increased gradually, about
one in every 250 people in some regions of developed
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countries [7] due to eradication of intestinal helminths
and improved domestic hygiene, and is inclined to
spread to less-developed countries [8, 9]. In line with the
theory of hygiene hypothesis, pre-infections with hel-
minths or treatment with immunomodulatory helminth-
derived proteins could suppress inflammation of colitis,
which is supported by several studies [10–12]. Infections
with Heligmosomoides polygyrus have preventative ef-
fects on TNBS-induced colitis [13, 14]. Infections with
Trichinella spiralis [15] or treatment with its larval anti-
gens [16] also display a protective role in dinitrobenzene
sulfonate (DNBS)-induced colitis. Besides, the prophy-
laxis effect of eggs or soluble proteins from Schistosoma
mansoni on colitis in mice has been found to be associ-
ated with down-regulation of the mRNA relative expres-
sion of the pro-inflammatory cytokines such as IFNγ
and IL-17A, and up-regulation of the anti-inflammatory
cytokine IL-4 in the colon [17].
Cystatin, an inhibitor of cysteine protease, comprises a
family of cysteine protease inhibitors in various hel-
minthes [18]. It has been reported as an important
pathogenicity factor and plays a significant role in sup-
pressing the immune response by regulating inflamma-
tory cytokines [19–23]. Cystatin, which belongs to a
large super family of binding inhibitors that interact with
papain-like cysteine proteases, has caused much concern
of interest with some exciting results, such as its in-
volvement in parasite protease regulation during the
molting process of Onchocerca volvulus [24, 25], and its
modulation of host immune response or inhibition of
host cathepsins [26, 27]. Up to now, only two schisto-
some cystatins have been trialed at the protein level
from S. mansoni and S. japonicum [28, 29]. The full
length of genomic DNA sequence of cystatin from S.
japonicum was available with accession number
FJ617451 in GenBank database and the full-length
cDNA sequence of Sjcystatin with accession number
FJ617450 in GenBank database which was inferred to
possess an opening reading frame (ORF) of 306 bp en-
coding 101 amino acids, with a predicted molecular
weight of 11.3 kDa, belonging to family I (stefins) [29].
The recombinant Sjcystatin has been purified and tested
to have the inhibitory activity against the cysteine prote-
ase papain [29]. Type II family cystatin from S. japoni-
cum was recently reported to have a regulatory effect on
macrophage skewing in vitro by inhibiting LPS-induced
TNF-α and IL-6 production in activated RAW264.7
[30].. The in vivo activity of S. japonicum cystatin has
not been examined so far although it is involved in the
in vitro modulation of host immune responses.
In the present study, we observed the therapeutic po-
tential of recombinant cystatin of S. japonicum (family I)
in TNBS-induced colitis in Balb/c mice. Additionally, we
investigated the underlying immunological mechanism
of the beneficial effect of rSjcystatin, mainly on Th1,
Th2, Th17 and Tregs by determining the cytokine profile
of T helper cells isolated from the spleens, mesenteric
lymph nodes and the colons, so as to provide a promis-
ing strategy for IBD treatment without the infeasible
helminth infections in clinical practice.
Methods
Animals and TNBS-induced colitis
Female Balb/c mice (specific pathogen free, SPF) of 6 to
8 weeks of age, weighing 18-20 g, were purchased from
the Animal Center of Anhui Medical University and
allowed to adapt for 4 days before the experiment with
food and water free to drink and eat under standard
conditions. All procedures were in strict accordance
with the Chinese National Institute of Health Guide for
the Care and Use of Laboratory Animals, and approved
by the Animal Care and Use Committee of Anhui Med-
ical University (approval no: AMU26-08061). Efforts
were made to minimize the number of animals and
their sufferings.
Colitis was generated by intrarectal administration of
TNBS solution (sigma, USA). Briefly, mice were fasted
for 24 h with free access to drinking water and then
were pressed lightly on the abdomen to facilitate intes-
tinal emptying and anesthetized using sodium pentobar-
bital (50 mg/kg, ip). Next, the mixture (5 % TNBS and
absolute ethyl ethanol with ratio 1:1) was administrated
intrarectally via a flexible catheter of 3.5 cm length.
After TNBS injection, mice were held in a vertical pos-
ition for 2 min to prevent leakage of the TNBS mixture
and then replaced in the cages with free access to food
and water.
Preparation of recombinant cystatin from S.japonicum
The pET-28a-Sjcystatin plasmid was transformed into
E.coli BL 21 for large scale expression of the recombin-
ant protein induced by 1 mM of isopropylthio-β-
galactoside (IPTG, sigma, USA) at 37 °C. The fusion
expression of rSjcystatin was purified with a Ni–NTA
His* Bind Purification Kit (Merck Millipore, USA). Pro-
tein concentration was examined using a Bicinchoninic
Acid Protein Assay Kit (Beyotime Biotechnology, China).
Animal preparation
Mice were divided into ①group TNBS-rSjcystatin,
treated with 50 μg rSjcystatin by intraperitoneal injection
(i.p.) 6 h and 24 h after TNBS administration; ②group
rSjcystatin-TNBS, treated with 50 μg rSjcystatin by i.p.
three times at 5d intervals before introduction of colitis;
③group TNBS, treated with TNBS followed by PBS in-
traperitoneal injection of the same volume as rSjcystatin;
④group rSjcystatin-PBS, treated with 50 μg rSjcystatin
by i.p. three times at 5d intervals followed by PBS given
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intrarectally with the same volume of TNBS mixture;
⑤group PBS-rSjcystatin, treated with 50 μg rSjcystatin
by i.p. 6 h and 24 h after PBS given intrarectally with the
same volume of TNBS mixture; and ⑥control, injected
intrarectally with PBS followed by PBS i.p. in parallel to
experimental groups. Three days after colitis induction,
mice were sacrificed under euthanasia. Inflammation
was determined based on 5 parameters: clinical disease
activity, shortening of colon length, macroscopic and
microscopic inflammation score, and myeloperoxidase
activity in the colon tissue. The grades were conveyed by
an investigator blinded for the treatment groups.
Lymphocytes were isolated from the spleens, mesen-
teric lymph nodes and colons. IFNγ, IL-4, IL-17A, and
Tregs were tested by FCM, mRNA relative expressions
of cytokines by qRT-PCR and concentrations of the cy-
tokines in colon homogenates tested by ELISA as well as
key transcription factors detected by Western blotting.
Clinical scoring of disease
The mice of each group were observed daily and given a
clinical disease score (disease activity index, DAI) ran-
ging from 0 to 12 based on the clinical manifestations of
weight loss, diarrhea, and bloody stool [31] (Table 1).
Macroscopic inflammation scoring
After being sacrificed, the colon was removed and care-
fully opened longitudinally. The colonic damage was
evaluated macroscopically on the following parameters:
extent of adhesions; degree of colonic ulcerations; co-
lonic wall thickness; and degree of mucosal oedema.
Each parameter was scored between 0 (normal) and 3
(severe) as described previously [32]. The total score was
presented from a minimum of 0 to a maximum of 12.
The length of colon, for evaluation of the extent of in-
flammation, was also measured [33].
Microscopic inflammation scoring
Colonic segments ready for histopathology examination
were fixed in 10 % formalin, then embedded into paraf-
fin, carefully sectioned at 5 μm thickness and stained
with hematoxylin and eosin. The histological damage
scoring was applied to grade the severity of inflamma-
tion based on the 2 following parameters: epithelial le-
sion (0, none damage; 1, some loss of goblet cells; 2,
extensive loss of goblet cells; 3, some loss of crypts; 4,
extensive loss of crypts); infiltration (0, none infiltration;
1, infiltration around crypt bases; 2, infiltration spread-
ing to muscularis mucosa; 3, extensive infiltration in the
muscularis mucosa with abundant oedema; 4, infiltration
spreading to submucosa). The total histological grade
ranged from a minimum of 0 to a maximum of 8 as
stated above [34].
MPO activity assay
Myeloperoxidase (MPO) activity was measured by using
a MPO assay kit (Nanjing Jiancheng Bio-engineering
Institute, China) to detect the degree of myeloid cell in-
filtration in the colon. Briefly, 100 mg colon tissues were
weighed and cut, followed by homogenizing in solution
containing 0.9 ml of saline, pH 6.0, 0.5 % hexadecyltri-
methyl ammonium hydroxide, and then centrifuged at
12,000 rpm (4 °C) for 15 min. The protein concentration
of the colon homogenate supernatants was examined
using a Bicinchoninic Acid Protein Assay Kit (Beyotime
Biotechnology, China). One hundred microliters of the
supernatants were collected and went on following
manufacture’ s instructions. The MPO activity of the
supernatants was determined and expressed as units per
gram of total protein (U/g).
Cell isolation and preparation
Spleens and MLNs were removed aseptically from
experimental mice, and then gently ground in the RPMI
1640 medium. The cells were harvested after mashing
through 75 μm cell strainer and suspended in RPMI
1640 supplemented with 10 % bovine fetal serum,
2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin. LPMCs were isolated as follows [13].
Briefly, colons were opened longitudinally, cut into
0.5 cm pieces after washing thoroughly, and then incu-
bated in D-hank’s with 0.5 mM EDTA at 37 °C for
20 min with gentle shaking. After repeating twice, the
tissue was incubated for 35 min at 37 °C in 20 ml RPMI
1640 containing 25 mM HEPES buffer, 2 mM L-glu-
tamine, 5 × 10−5 M β-mercaptoethanol,1 mM sodium
pyruvate, 100 U/ml penicillin, 10 mg/ml gentamycin,
100 mg/ml streptomycin, as well as 1 mg/ml collage-
nase IV (Sigma, American). The cell suspension was
filtered through a 100 μm filter and washed, and the
LPMCs were collected by discontinuous 40/70 % percol
gradient centrifugation.
Flow cytometry analysis of lymphocytes
Lymphocytes from spleens, mesenteric lymph nodes and
LPMCs were suspended again and adjusted to the
proper cell number. The lymphocytes were stimulated
with PMA and ionomycin for 4 h and Golgi inhibitor
was then added for the last 2 h of the culture. The cells
Table 1 Disease activity index score parameters (DAI)
Weight loss (%) Stool Bloody stool index
0-1 % normal none 0
1-5 % soft and shaped between 1
5-10 % loose slight 2
10-15 % between between 3
>15 % diarrhea gross bleeding 4
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were subjected to FITC-labeled anti-mouse CD4 (BD
Pharmingen), followed by PE-labeled anti-mouse IFNγ
(BD Pharmingen), APC-labeled anti-mouse IL-4 (BD
Pharmingen) and PE-labeled anti-mouse IL-17A (BD
Pharmingen) for intracellular cytokine staining after
using the Cytofix/Cytoperm kit (BD Pharmingen) ac-
cording to the manufactures’ instructions.
For Tregs examination, cells were first stained with
FITC-labeled anti-mouse CD4 and APC-labeled anti-
mouse CD25 (BD Pharmingen). After surface staining,
the cells were stained with PE-labeled anti-mouse Foxp3
antibodies after incubation with Fix/Perm Buffer (BD
Pharmingen) at 2-8 °C for 40–50 min in protection from
light. Cells were analysed on a flow cytometer.
RNA extraction and qRT-PCR
The total RNA of lymphocytes from the spleen and
MLN was extracted and then reversely transcribed to
cDNA using Prime Script 1st Strand cDNA Synthesis
Kit (Takara, Japan). A quantitative analysis of the relative
mRNA expression of different cytokines was performed
to determine the balance between Th1, Th17, Th2, and
Treg cells in the lymphocytes from spleen and MLN
using qRT-PCR. The parameters for PCR amplification
were 95 °C for 5 min, followed by 40 cycles of 95 °C for
10 s and 60 °C for 34 s. GAPDH was used as an en-
dogenous housekeeping gene to normalize the results.
The relative mRNA expression was calculated with the
comparative △Ct method using the formula 2-△△Ct. The
forward and reverse primers are listed in Table 2.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was used to detect values of cytokines in the
colon homogenate supernatants following the manufac-
tures’ instructions (RayBiotech, USA).
Western blotting of transcription factors in colon tissues
One hundred micrograms of colon homogenate proteins
were boiled with loading buffer and separated by 12 %
polyacrylamide gel electrophoresis. Proteins were blotted
onto a polyvinylidene fluoride (PVDF) membrane. Anti-
T-bet, Anti-GATA-3, Anti-Foxp3, and Anti-RORγ(t)
were applied at proper dilution ratio and GAPDH was
used at 1:2000.
Statistical analysis
Data were evaluated and analysed using a one-way
ANOVA analysis and SPSS 16.0 software. P < 0.05 was
considered as statistically significant. All statistical ana-
lysis were performed using GraphPad Prism software.
Results
Effect of rSjcystatin on alleviation of the severity of TNBS-
induced colitis
The inflammation was evaluated for weight loss, stool
character and expressed as DAI. Three days post-TNBS
administration, mice developed significant colitis with
manifestations of weight loss, diarrhea, bleeding faeces,
and physical weakness compared to the control group
treated with PBS only. No macro and microscopic
lesions were found in control animals. Weight loss of
the experimental mice reached to the maximum of 15 %
3 days post-TNBS administration when DAI increased
to (7.60 ± 1.10) vs (8.33 ± 1.97) (P > 0.05) in the group of
mice with injection of 50 μg rSjcystatin three times prior
to colitis. Mice of group rSjcystatin-TNBS developed se-
vere inflammation as TNBS-induced colitis of mice at
the level of MPO (0.92 ± 0.28 vs 1.45 ± 0.52) U/g, MAO
(7.14 ± 0.69 vs 7.83 ± 0.98) and MIO (5.17 ± 0.75 vs 6.17
± 1.72) 3 days afterwards (Fig. 1). While injected twice
with 50 μg rSjcystatin after colitis, mice showed a signifi-
cantly lower levels of MPO (0.59 ± 0.23) U/g, MAO
(4.71 ± 1.11), MIO (3.50 ± 0.55), DAI (4.80 ± 0.84) and
less colon shrinkage than the untreated colitis mice
(Figs. 2, 3).
Measurements of the inflammatory cytokine profiles
We examined the IFNγ for Th1 response, IL-4 for Th2
response, IL-17A for Th17 and Tregs in the lymphocytes
in the spleen, MLN and LPMCs. Compared to the
control, Th1 cell populations (CD4+IFNγ+) and Th17
subsets (CD4+IL-17A+) increased in the spleen, MLN
and colon tissues of mice with colitis (Fig. 4a, c) as well
as the enhanced concentrations of IFNγ and IL-17 in
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colon homogenate supernatants (Fig. 6a). The rSjcystatin
application after colitis decreased the proportion of Th1
subsets in these organs, due to the data of the percent-
age of CD4+IFNγ+ and relative expression of IFNγ
mRNA descended in the spleen and MLN (Fig. 5).
Meantime, treatment with rSjcystatin after TNBS induc-
tion also led to significant decline of the percentage of
CD4+IFNγ+ in the LPMC (Fig. 4e), which was confirmed
in colon homogenate supernatants by ELISA, showing a
statistical I difference of IFNγ between mice with colitis
(1628.6 ± 358.51) pg/ml and mice treated with TNBS-
rSjcystatin (1126.8 ± 230.16) pg/ml (Fig. 6a).
Unexpectedly, the percentages of CD4+IL-17A+ in the
lymphocytes of spleen, MLN and LPMCs exhibited no
Fig. 1 rSjcystatin injection prior to colitis failed to decrease inflammatory index. Disease activity index was evaluated during the experimental
period a Weight change b The colons of four groups were removed and the length was measured and recorded c, with MPO activity d tested,
as well as Macroscopic e and Microscopic score f No statistical difference of the inflammatory index was displayed between group rSjcystatin-
TNBS and group TNBS
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significant difference in the groups of TNBS and TNBS-
rSjcystatin (Fig. 4e). Also, the level of Th17 presented no
difference in colon homogenate supernatants of mice in
the same groups tested by ELISA and in its transcription
factor RORγ(t) detected by protein blotting (Fig. 6).
Moreover, we failed to observe discrepancy in the per-
centage of CD4+IL-4+ in the group of TNBS-rSjcystatin
and group of TNBS in the three organs (Fig. 4b). But the
concentrations of IL-4 (159.95 ± 30.66) pg/ml and IL-13
(8623.1 ± 1644.19) pg/ml in the colon homogenates rose
more sharply in the group of TNBS-rSjcystatin when
examined by ELISA (Fig. 6a).
As for Tregs, no remarkable difference was noted in
the spleen. Tregs number was increased in MLN and
LPMC of mice in the group treated with TNBS-
rSjcystatin (Fig. 4d). Consistent with the Tregs tested by
flow cytometry, relative mRNA expressions of Foxp3,
IL-10 and TGF-β in MLNs of mice in the group TNBS-
rSjcystatin were markedly enhanced compared with
TNBS-treated animals (Fig. 5). In addition, the levels of
IL-10 (455.51 ± 187.87) pg/ml and TGF-β (116.18 ±
17.68) pg/ml were elevated higher in the colon
homogenate supernatants of mice in the TNBS-
rSjcystatin group than in the TNBS group (Fig. 6a).
In order to obtain the most accurate immunological
data, we identified the transcription factors of Th1
(T-bet), Th2 (GATA-3), Th17 (RORγ(t)) and Tregs
(Foxp3) in colon tissues by Western blotting. GATA-3
and Foxp3 were expressed more highly in mice of
group TNBS-rSjcystatin than in mice with colitis,
while a low expression of T-bet was seen after rSjcys-
tatin treatment except that RORγ(t) stayed nearly the
same in those two experimental groups (Fig. 6b).
Discussion
Plenty of evidence has demonstrated that helminth and
helminth derived products have the ability to suppress
the development of IBDs [35–39], mainly through
down-regulating Th1 and Th17 responses. The influence
of the molecules from S. japonicum have not been
reported on TNBS-induced colitis so far. Thus the
present study aimed to investigate the therapeutic role
of rSjcystatin in TNBS-induced colitis in mice. Cystatin,
an inhibitor of cysteine protease, was regarded as a key
Fig. 2 Treatment of rSjcystatin after colitis could diminish colonic inflammation. Colons were removed and shown in (a), length was measured
with the result of less colon shrinkage in group TNBS-rSjcystatin than group of the untreated colitis mice (b), inflammatory cell infiltration in the
colon histological sections (c)
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molecule in protein degradation as well as in antigen
presentation, apoptosis, protein processing, and inflam-
mation and cancer progression [40–44]. It was reported
that cystatin of filaria may sharpen T cell proliferation
and enhance IL-10 production [20]. Cystatin from
Acanthocheilonema viteae was noted to be responsible
for amelioration of colitis in mice [45].
In the present study, we generated colitis in mice by
TNBS, which resembled human inflammatory bowel
disease [46] in weight loss, diarrhea, bloody stool, and
increased DAI, macro and microscopic score and MPO.
Here we found an alleviated inflammation in the colon
with low inflammation index when the rSjcystatin was
administrated to the mice with colitis at a dose of 50 μg
twice after modeling. Unexpectedly, the rSjcystatin, if
given to mice before TNBS induction, failed to decrease
the levels of DAI, MPO and other inflammation indexes
compared to the mice with colitis, suggesting an un-
ascertainable preventative effect of rSjcystatin on TNBS-
induced colitis. It is indicated that rSjcystatin acted as an
immunoregulator only when the lymphocytes were
activated under the inflammatory circumstances.
TNBS-mediated colitis is mainly T cell dependent and
CD4+T cells are dominantly involved in the pathogenic
process [47]. Thus cytokines secreted from CD4+T
subsets are the value of the targets and will be a poten-
tial strategy in IBDs therapy. In the mouse model, we
demonstrated that colonic inflammation was caused by
the increase of Th1 response along with Th17 activation,
which showed the significantly high percentages of CD4
+IFNγ+ and CD4+IL17A+ in the spleen, MLN and LPMC
and the high concentrations of IFNγ and IL-17 in the
colon homogenates. It has been widely accepted that
Th1 response dominates in the TNBS-induced colitis
while IL-17A seems not to be necessary in the T-cell
mediated model of colitis [48]. In the present study, the
percentage of CD4+IFN+ decreased in the group TNBS-
rSjcystatin whereas CD4+IL17A+ cells did not show a
statistically significant decline, suggesting that rSjcystatin
might relieve local inflammation through down-
regulating Th1 rather than Th17 response. The result is
parallel to the cytokine assay by ELISA and Western
blotting in colon tissues. Additionally, Th17 pathobiol-
ogy is still under controversy for its plastic roles in
different experimental models of colitis, distinguished by
their function as either “pathogenic” or “nonpathogenic”
[49]. It has been reported that IL-17 antibody in the
progress of acute colitis amplified the colon inflamma-
tion [50] although IL-17A deficiency was found to be
able to ameliorate colitis in mice [51].
Fig. 3 rSjcystatin application lowered the inflammatory index in the mice of TNBS-rSjcystatin group. Disease activity index was evaluated during
the experimental period (a) Weight loss was monitored daily (b) MPO activity, Macroscopic and Microscopic scores in the colon of four groups
were compared (c) (*p < 0.05). Statistical difference of the inflammatory index was displayed between group TNBS-rSjcystatin and group TNBS
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Fig. 4 Treatment of rSjcystatin after colitis reduced the percentage of Th1 cell population (CD4+IFNγ+) in three organs (a), increased regulatory T
cells (Treg) in the MLN and LPMC (D-2,D-3). No statistical difference of the percentage of Th2 subsets (CD4+IL-4+) and Th17 subsets (CD4+IL-17A+)
was noted between colitis group and TNBS-rSjcystatin group (b,c). The data were compared (*p < 0.05) (e)
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Fig. 5 (See legend on next page.)
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(See figure on previous page.)
Fig. 5 mRNA relative expressions of inflammatory and anti-inflammatory cytokines in the lymphocytes of spleen (a) and MLN (b) were examined
by qRT-PCR (*p < 0.05), showing that IFNγ mRNA expression in the lymphocytes of spleen and MLN increased sharply in the group TNBS, and
declined after rSjcystatin application. Nevertheless, IL-10, TGF-β, Foxp3 mRNA relative expressions were lifted in the lymphocytes of MLN but not
in the lymphocytes of spleen when rSjcystatin was injected after colitis induction
Fig. 6 The concentrations of inflammatory and anti-inflammatory cytokines in the colon homogenate supernatants were tested by ELISA (a). The level of
IFNγ and IL-17 in the colon homogenate supernatants were enhanced in group TNBS, and the level of IFNγ decreased after rSjcystatin injection but IL-17
rejected to decline, while the levels of IL-4, IL-13, IL-10 and TGF-β increased after rSjcystatin injection. Transcription factors of Th1, Th2, Th17, and Treg were
detected by Western blotting in the colon tissue (b). Higher expressions of GATA-3 and Foxp3 were shown in mice of group TNBS-rSjcystatin than in mice
with colitis while a low expression of T-bet was seen after rSjcystatin treatment except that RORγ(t) stayed nearly the same in those two
experimental groups
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It is obvious that the Th2 response was initiated in the
colon tissue of group TNBSrSjcystatin since high con-
centrations of IL-4 and IL-13 were noted in colon tissue
homogenates, which was verified by its transcription
factor GATA-3 protein blotting. Thus a biased Th2
response might be induced by rSjcystatin in the inflam-
mation loci, acting as anti-inflammatory factors down-
regulating Th1 response and restraining the colonic
inflammation. Similar results have been seen in SEA of
S.mansoni and in the egg-stage specific antigen from S.
japonicum that Th2 response was evoked by helminth
derived molecules such as omega-1, IPSE/alpha-1 and
Cyclophilin A [52–55]. It may be expected that activa-
tion of IL-13 [56] and IL-4 signaling might be a potential
therapeutic strategy in IBDs. In contrast, IL-4-producing
effector T cells in LPMC were not discovered to be at
high levels in the mice as expected, which was well in
line with the previous report that cytokine detection
with ELISA is not necessarily parallel to the intracellular
staining analysis by flow cytometry [57].
It has been clarified that regulatory T cells (Tregs) play
a crucial role in protection of IBDs in both humans and
animals [58, 59]. We discovered that the number of CD4
+CD25+Foxp3+ cells stayed stable in the spleens of all
experimental groups but dramatically increased in the
MLN of the TNBS-rSjcystatin treated mice. Correspond-
ingly, a significant elevation of IL-10, TGF-β and Foxp3
mRNA expressions was found in the MLN of group
TNBS-rSjcystatin. Interestingly, numerous unconven-
tional Tregs of CD4+CD25−Foxp3+ were remarkably
increased in the LPMCs of colitis mice followed by
rSjcystatin injection compared to the mice with colitis. It
can be explained by the fact that CD4+CD25−Foxp3+ T
cells are the dominant Tregs population in the gut, lung
and liver [60] with suppressive activity both in rodents
and humans [61, 62]. Similar outcomes of CD4+CD25−
Foxp3+ T cells and their functions were reported in
animal models of experimental colitis [63]. It is Foxp3
but not CD25 expression that plays an important role in
Tregs functioning of the mouse model [61, 64]. Thus we
presumed that this phenomenon might be linked to use
of purified protein which took responsibility for the
uptrend of CD4+CD25−Foxp3+ population [65]. In
accordance with elevated numbers of Th2 and Tregs, IL-
10 and TGF-β were simultaneously expressed highly in
the homogenates of colon tissues.
We noted that the effect of rSjcystatin was so obvious
when given 6 and 24 h after TNBS injection and experi-
mental colitis was significantly dampened 3 days later.
Previous researches indicated that macrophages in the
intestinal mucosa play a crucial role in the pathogenesis
of IBD: low production of inflammatory mediators by
macrophage caused by impaired innate immunity results
in Crohn’s disease [66, 67]. Thus we presume that
rSjcystatin may induce the intestinal macrophages to be
more functional as alternatively activated macrophages
(M2-like cells) since elevated concentrations of IL-10
and TGF-β in the colon homogenate supernatants were
noted. Schnoeller et al. also found that the recombinant
cystatin from the filaria A. viteae in vivo inhibited acute
colitis of mice probably via enhancing IL-10 production
by macrophages [45]. Recently, Jang et al. tested recom-
binant cystatin from Clonorchis sinensis in colitis of mice
and showed that it could reduce intestinal inflammation
related with the recruitment of IL-10 secreting alterna-
tively activated macrophages [68]. The M2-like cells
involved in innate immunity may account for the down-
regulated impact of rSjcystatin on the proinflammatory
cytokine profile in the model colitis although more
approaches would need to be done. Additionally, the
biological activity of the in vivo effects of rSjcystatin as a
protease inhibitor cannot be ruled out due to the fact
that rSjcystatin is able to inhibit cysteine protease which
is required for the antigen procession and presentation
of APCs (antigen presenting cells). So we believe that
rSjcystatin could alleviate the impaired host innate
immunity soon after being administered to mice with
TNBS-induced colitis, followed by initiating the adaptive
immunity to stimulate immune regulatory responses.
Further investigation would be needed to reveal the
precise mechanisms of the inhibitory effect of the
helminth-derived peptide on amelioration of inflamma-
tory bowel diseases via innate immunity stimulation.
Conclusions
Taken together, we demonstrated that the rSjcystatin,
derived from Schistosoma japonicum, may alleviate the
Th1 dominated immunopathogenesis and actively re-
strain the colonic inflammation in TNBS-induced
experimental colitis in mice. The up-regulation of Tregs
and Th2 skewed response induced by rSjcystatin in the
local inflammatory tissues might be involved in the ame-
liorated process of colitis.
Abbreviations
APCs: Antigen presenting cells; DAI: Disease activity index;
DNBS: Dinitrobenzene sulfonate; DNBS: Dinitrobenzene sulfonate;
ELISA: Enzyme-linked immunosorbent assay; IBD: Inflammatory bowel
disease; IPTG: Isopropylthio-β-galactoside; LPMCs: Intestinal lamina propria
mononuclear cells; M2: Alternatively activated macrophages;
MAO: Macroscopic score; MIO: Microscopic score; MLN: Mesenteric lymph
nodes; MPO: Myeloperoxidase activity; NO: Nitric oxide; PVDF: Polyvinylidene
fluoride; qRT-PCR: Quantitative real time reverse-transcriptase polymerase
chain reaction; SPF: Specific pathogen free; TNBS: Trinitrobenzene sulfonic
acid; TNF-α: Tumor necrosis factor alpha; Tregs: Regulatory T cells.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JLS, SSW and XDY conceived and designed the trial; SSW, XSW, YYX and KY
performed the experiments; XWW, YZ, and FL analysed the data; SSW wrote
Wang et al. Parasites & Vectors  (2016) 9:6 Page 11 of 13
the manuscript; JLS, YHX and SSW critically revised the manuscript. All
authors have read and approved the final manuscript.
Acknowledgments
We thank Dr. Li He at Basic Medical School of Wuhan University, for
providing recombinant plasmid. The work was funded by the National
Science Foundation of China (No. 81171606; No. 81441120), Science
Foundation of Anhui Province (No. 1308085MH124; No. 1508085QH158) and
the Science and Technology Department Foundation of Bengbu Medical
College (No. BYKF13A03).
Author details
1Department of Immunology, Anhui Medical University, Hefei 230022, China.
2Department of Pathogen Biology, Provincial Laboratories of Pathogen
Biology and Zoonoses Anhui, Hefei 230022, China. 3Pediatrics Department of
Affiliated Provincial Hospital, Anhui Medical University, Hefei 230001, China.
4Department of Microbiology and Parasitology, Bengbu Medical College;
Anhui Key Laboratory of Infection and Immunity, Bengbu 233000Anhui,
China. 5Department of Laboratory Diagnosis, the Affiliated Hospital of
Bengbu Medical College, Bengbu 233004, China. 6Department of Laboratory
Diagnosis, the First Affiliated Hospital of Anhui Medical University, Hefei
230022, China.
Received: 23 September 2015 Accepted: 28 December 2015
References
1. Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspring's
risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel
Dis. 2012;18(5):857–62.
2. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S,
et al. Impact of diet in shaping gut microbiota revealed by a comparative
study in children from Europe and rural Africa. Proc Natl Acad Sci U S A.
2010;107(33):14691–6.
3. Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel
diseases in childhood. Gut. 2011;60(1):49–54.
4. Fiocchi C. One commensal bacterial molecule–all we need for health?
N Engl J Med. 2005;353(19):2078–80.
5. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review
of medical therapy. World J Gastroenterol. 2008;14(3):354–77.
6. Bamias G, Cominelli F. Novel strategies to attenuate immune activation in
Crohn's disease. Curr Opin Pharmacol. 2006;6(4):401–7.
7. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al.
Increasing incidence and prevalence of the inflammatory bowel
diseases with time, based on systematic review. Gastroenterology.
2012;142(1):46–54. e42; quiz e30.
8. Shin DH, Sinn DH, Kim YH, Kim JY, Chang DK, Kim EJ, et al. Increasing
incidence of inflammatory bowel disease among young men in Korea
between 2003 and 2008. Dig Dis Sci. 2011;56(4):1154–9.
9. Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in
China. J Dig Dis. 2010;11(2):76–82.
10. Buning J, Homann N, von Smolinski D, Borcherding F, Noack F, Stolte M,
et al. Helminths as governors of inflammatory bowel disease. Gut. 2008;
57(8):1182–3.
11. Broadhurst MJ, Leung JM, Kashyap V, McCune JM, Mahadevan U,
McKerrow JH, et al. IL-22+ CD4+ T cells are associated with therapeutic
trichuris trichiura infection in an ulcerative colitis patient. Sci Transl
Med. 2010;2(60):60ra88.
12. Kabeerdoss J, Pugazhendhi S, Subramanian V, Binder HJ, Ramakrishna BS.
Exposure to hookworms in patients with Crohn's disease: a case–control
study. Aliment Pharmacol Ther. 2011;34(8):923–30.
13. Setiawan T, Metwali A, Blum AM, Ince MN, Urban Jr JF, Elliott DE, et al.
Heligmosomoides polygyrus promotes regulatory T-cell cytokine production
in the murine normal distal intestine. Infect Immun. 2007;75(9):4655–63.
14. Sutton TL, Zhao A, Madden KB, Elfrey JE, Tuft BA, Sullivan CA, et al. Anti-
Inflammatory mechanisms of enteric Heligmosomoides polygyrus infection
against trinitrobenzene sulfonic acid-induced colitis in a murine model.
Infect Immun. 2008;76(10):4772–82.
15. Khan WI, Blennerhasset PA, Varghese AK, Chowdhury SK, Omsted P, Deng Y,
et al. Intestinal nematode infection ameliorates experimental colitis in mice.
Infect Immun. 2002;70(11):5931–7.
16. Motomura Y, Wang H, Deng Y, El-Sharkawy RT, Verdu EF, Khan WI. Helminth
antigen-based strategy to ameliorate inflammation in an experimental
model of colitis. Clin Exp Immunol. 2009;155(1):88–95.
17. Elliott DE, Li J, Blum A, Metwali A, Qadir K, Urban Jr JF, et al. Exposure to
schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol
Gastrointest Liver Physiol. 2003;284(3):G385–391.
18. Kordis D, Turk V. Phylogenomic analysis of the cystatin superfamily in
eukaryotes and prokaryotes. BMC Evol Biol. 2009;9:266.
19. Hartmann S, Adam R, Marti T, Kirsten C, Seidinger S, Lucius R. A 41-kDa
antigen of the rodent filaria Acanthocheilonema viteae with homologies to
tropomyosin induces host-protective immune responses. Parasitol Res.
1997;83(4):390–3.
20. Hartmann S, Kyewski B, Sonnenburg B, Lucius R. A filarial cysteine protease
inhibitor down-regulates T cell proliferation and enhances interleukin-10
production. Eur J Immunol. 1997;27(9):2253–60.
21. Manoury B, Gregory WF, Maizels RM, Watts C. Bm-CPI-2, a cystatin homolog
secreted by the filarial parasite Brugia malayi, inhibits class II MHC-restricted
antigen processing. Curr Biol. 2001;11(6):447–51.
22. Schierack P, Lucius R, Sonnenburg B, Schilling K, Hartmann S. Parasite-
specific immunomodulatory functions of filarial cystatin. Infect Immun.
2003;71(5):2422–9.
23. Harnett W. Secretory products of helminth parasites as immunomodulators.
Mol Biochem Parasitol. 2014;195(2):130–6.
24. Lustigman S, Brotman B, Huima T, Prince AM. Characterization of an
Onchocerca volvulus cDNA clone encoding a genus specific antigen
present in infective larvae and adult worms. Mol Biochem Parasitol. 1991;
45(1):65–75.
25. Lustigman S, Brotman B, Huima T, Prince AM, McKerrow JH. Molecular
cloning and characterization of onchocystatin, a cysteine proteinase
inhibitor of Onchocerca volvulus. J Biol Chem. 1992;267(24):17339–46.
26. Newlands GF, Skuce PJ, Knox DP, Smith WD. Cloning and expression of
cystatin, a potent cysteine protease inhibitor from the gut of Haemonchus
contortus. Parasitology. 2001;122(Pt 3):371–8.
27. Vray B, Hartmann S, Hoebeke J. Immunomodulatory properties of cystatins.
Cell Mol Life Sci. 2002;59(9):1503–12.
28. Morales FC, Furtado DR, Rumjanek FD. The N-terminus moiety of the
cystatin SmCys from Schistosoma mansoni regulates its inhibitory activity in
vitro and in vivo. Mol Biochem Parasitol. 2004;134(1):65–73.
29. He B, Cai G, Ni Y, Li Y, Zong H, He L. Characterization and expression of a
novel cystatin gene from Schistosoma japonicum. Mol Cell Probes. 2011;
25(4):186–93.
30. Yang X, Liu J, Yue Y, Chen W, Song M, Zhan X, et al. Cloning,
expression and characterisation of a type II cystatin from Schistosoma
japonicum, which could regulate macrophage activation. Parasitol Res.
2014;113(11):3985–92.
31. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, et al. Distinct
cytokine patterns identified from multiplex profiles of murine DSS and
TNBS-induced colitis. Inflamm Bowel Dis. 2009;15(3):341–52.
32. Menachem Y, Trop S, Kolker O, Shibolet O, Alper R, Nagler A, et al.
Adoptive transfer of NK 1.1+ lymphocytes in immune-mediated colitis:
a pro-inflammatory or a tolerizing subgroup of cells? Microbes and
infection / Institut Pasteur. 2005;7(5–6):825–35.
33. Axelsson LG, Landstrom E, Bylund-Fellenius AC. Experimental colitis induced
by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and
olsalazine. Aliment Pharmacol Ther. 1998;12(9):925–34.
34. Obermeier F, Kojouharoff G, Hans W, Scholmerich J, Gross V, Falk W.
Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced
nitric oxide as toxic effector molecule in chronic dextran sulphate sodium
(DSS)-induced colitis in mice. Clin Exp Immunol. 1999;116(2):238–45.
35. Ruyssers NE, De Winter BY, De Man JG, Loukas A, Pearson MS, Weinstock JV,
et al. Therapeutic potential of helminth soluble proteins in TNBS-induced
colitis in mice. Inflamm Bowel Dis. 2009;15(4):491–500.
36. Heylen M, Ruyssers NE, De Man JG, Timmermans JP, Pelckmans PA, Moreels
TG, et al. Worm proteins of Schistosoma mansoni reduce the severity of
experimental chronic colitis in mice by suppressing colonic
proinflammatory immune responses. PLoS One. 2014;9(10), e110002.
37. Yang X, Yang Y, Wang Y, Zhan B, Gu Y, Cheng Y, et al. Excretory/secretory
products from Trichinella spiralis adult worms ameliorate DSS-induced
colitis in mice. PLoS One. 2014;9(5), e96454.
38. Leung J, Hang L, Blum A, Setiawan T, Stoyanoff K, Weinstock J.
Heligmosomoides polygyrus abrogates antigen-specific gut injury in a
Wang et al. Parasites & Vectors  (2016) 9:6 Page 12 of 13
murine model of inflammatory bowel disease. Inflamm Bowel Dis. 2012;
18(8):1447–55.
39. Ferreira I, Smyth D, Gaze S, Aziz A, Giacomin P, Ruyssers N, et al. Hookworm
excretory/secretory products induce interleukin-4 (IL-4) + IL-10+ CD4+ T cell
responses and suppress pathology in a mouse model of colitis. Infect
Immun. 2013;81(6):2104–11.
40. Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen
presentation. Nat Rev Immunol. 2003;3(6):472–82.
41. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities.
EMBO J. 2001;20(17):4629–33.
42. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target
proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep.
1998;5(6):1349–61.
43. Lang A, Horler D, Baici A. The relative importance of cysteine peptidases in
osteoarthritis. J Rheumatol. 2000;27(8):1970–9.
44. Nixon RA, Cataldo AM, Mathews PM. The endosomal-lysosomal system of
neurons in Alzheimer's disease pathogenesis: a review. Neurochem Res.
2000;25(9–10):1161–72.
45. Schnoeller C, Rausch S, Pillai S, Avagyan A, Wittig BM, Loddenkemper C,
et al. A helminth immunomodulator reduces allergic and inflammatory
responses by induction of IL-10-producing macrophages. J Immunol. 2008;
180(6):4265–72.
46. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of
inflammatory bowel disease. Gastroenterology. 1995;109(4):1344–67.
47. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse
models of intestinal inflammation. Nat Protoc. 2007;2(3):541–6.
48. Izcue A, Hue S, Buonocore S, Arancibia-Carcamo CV, Ahern PP, Iwakura Y,
et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-
dependent colitis. Immunity. 2008;28(4):559–70.
49. O'Connor Jr W, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al. A
protective function for interleukin 17A in T cell-mediated intestinal
inflammation. Nat Immunol. 2009;10(6):603–9.
50. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of
interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice.
Clin Immunol. 2004;110(1):55–62.
51. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-
17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis.
2006;12(5):382–8.
52. Schramm G, Haas H. Th2 immune response against Schistosoma mansoni
infection. Microbes and infection / Institut Pasteur. 2010;12(12–13):881–8.
53. Schramm G, Mohrs K, Wodrich M, Doenhoff MJ, Pearce EJ, Haas H, et al.
Cutting edge: IPSE/alpha-1, a glycoprotein from Schistosoma mansoni eggs,
induces IgE-dependent, antigen-independent IL-4 production by murine
basophils in vivo. J Immunol. 2007;178(10):6023–7.
54. Schramm G, Falcone FH, Gronow A, Haisch K, Mamat U, Doenhoff MJ, et al.
Molecular characterization of an interleukin-4-inducing factor from
Schistosoma mansoni eggs. J Biol Chem. 2003;278(20):18384–92.
55. Li J, Zhuang W, Cong L, Shi W, Xingyan C, Huang F, et al. Cyclophilin A
from Schistosoma japonicum promotes a Th2 response in mice. Parasites
&Vectors. 2013;6:330.
56. Wilson MS, Ramalingam TR, Rivollier A, Shenderov K, Mentink-Kane MM,
Madala SK, et al. Colitis and intestinal inflammation in IL10−/− mice results
from IL-13Ralpha2-mediated attenuation of IL-13 activity. Gastroenterology.
2011;140(1):254–64.
57. Alheim M, Lazdina U, Milich DR, Sallberg M. Flow cytometric determination
of cytokine production and proliferation in hepatitis B core antigen specific
murine CD4 cells: lack of correlation between number of cytokine
producing cells and cytokine levels in supernatant. J Immunol Methods.
2001;258(1–2):157–67.
58. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+
regulatory T cells. Nat Rev Immunol. 2011;11(2):119–30.
59. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal
inflammation. Annu Rev Immunol. 2009;27:313–38.
60. Coleman MM, Finlay CM, Moran B, Keane J, Dunne PJ, Mills KH. The
immunoregulatory role of CD4 + FoxP3 + CD25_ regulatory T cells in lungs
of mice infected with Bordetella pertussis. FEMS Immunol Med Microbiol.
2012;64(3):413–24.
61. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY.
Regulatory T cell lineage specification by the forkhead transcription factor
foxp3. Immunity. 2005;22(3):329–41.
62. Ono M, Shimizu J, Miyachi Y, Sakaguchi S. Control of autoimmune
myocarditis and multiorgan inflammation by glucocorticoid-induced TNF
receptor family-related protein(high), Foxp3-expressing CD25+ and CD25-
regulatory T cells. J Immunol. 2006;176(8):4748–56.
63. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A,
Bandeira A. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T
cells through the production of IL-10. J Immunol. 2001;166(5):3008–18.
64. Hasby EA, Hasby Saad MA, Shohieb Z, El Noby K. FoxP3+ T regulatory cells
and immunomodulation after Schistosoma mansoni egg antigen
immunization in experimental model of inflammatory bowel disease. Cell
Immunol. 2015;295(1):67–76.
65. Radovic I, Gruden-Movsesijan A, Ilic N, Cvetkovic J, Mojsilovic S, Devic M,
et al. Immunomodulatory effects of Trichinella spiralis-derived excretory-
secretory antigens. Immunol Res. 2015;61(3):312–25.
66. Marks DJ, Segal AW. Innate immunity in inflammatory bowel disease: a
disease hypothesis. J Pathol. 2008;214(2):260–6.
67. Comalada M, Peppelenbosch MP. Impaired innate immunity in Crohn’s
disease. Trends Mol Med Trends Mol Med. 2006;12(9):397–9.
68. Jang SW, Cho MK, Park MK, Kang SA, Na BK, Ahn SC, et al. Parasitic
Helminth Cystatin Inhibits DSS-Induced Intestinal Inflammation Via IL-10 +
F4/80+ Macrophage Recruitment. Korean J Parasitol. 2011;49(3):245–54.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. Parasites & Vectors  (2016) 9:6 Page 13 of 13
